Results 61 to 70 of about 13,127 (167)
Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates [PDF]
, 2022 International audienceAbstract The COVID-19 pandemic has exemplified that rigorous evaluation in large animal models is key for translation from promising in vitro results to successful clinical implementation.
van der Werf, Sylvie +26 more
core +1 more source
Favipiravir as RNA Polymerase Dependent (Rdrp) in COVID-19 [PDF]
, 2021 Coronavirus disease 2019 or Coronavirus disease 2019 (COVID-19) is a contagious disease caused by a new virus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). This disease became a pandemic and is being discussed around world because it has
Suharto, Fadel Fikri
core +1 more source
MedComm, Volume 7, Issue 9, September 2026.SARS‐CoV‐2 infection causes COVID‐19 and stimulates immune cells, such as dendritic cells, monocytes, and macrophages, to increase levels of many cytokines. Ursodeoxycholic acid (UDCA) inhibits farnesoid X receptor (FXR), resulting in a decrease in the activity of angiotensin‐converting enzyme 2 (ACE2), the main receptor on the membrane for SARS‐CoV‐2.
Zhaowei Tong +8 more
wiley +1 more source
Sleep Research, Volume 3, Issue 3, Page 242-250, September 2026.Abstract Background Obstructive sleep apnea (OSA) frequently co‐occurs with major depressive disorder (MDD). However, the underlying biological mechanisms remain unclear. This study aimed to identify OSA‐related transcriptional signatures associated with depressive status using integrated bioinformatics and machine learning.
Yun‐Shu Sun +5 more
wiley +1 more source
New insights into electronic and adsorption energies of metallofullerenes C19M
Results in Materials, 2023 A comprehensive electronic investigation was carried out by G09W program to provide new insights into the adsorption energies of metallofullerenes C19M (M = Sc, Ti, V, Cr, Mn, Fe, Co, Ni, Cu and Zn). In this regard, the DFT calculations were performed on
A.A. El-Barbary, I.F.M. AL-Dosari
doaj +1 more source
British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2390-2402, July 2026.Aims The repurposed use of favipiravir in COVID‐19 has been reported to have limited clinical efficacy, yet it has been widely used in some countries. Favipiravir causes mutagenesis in RNA viruses, and it is currently unknown whether it may have a measurable effect on the virus in humans.
Akosua A. Agyeman +9 more
wiley +1 more source
BMC Chemistry, 2023 Background Favipiravir is currently used for the treatment of coronavirus disease-2019 (COVID-19). Objective A highly sensitive and eco-friendly electroanalytical method was developed to quantify favipiravir.
Heba M. El-Sayed +4 more
doaj +1 more source
Advancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery
Chemical Biology &Drug Design, Volume 108, Issue 1, July 2026.A stepwise translational framework linking natural‐product discovery, computational prioritisation, experimental validation, lead optimisation and targeted delivery is proposed to advance antiviral design. ABSTRACT The COVID‐19 pandemic highlighted the role of rapid viral mutation and global connectivity in accelerating viral emergence and spread ...
Adedayo Ayodeji Lanrewaju +3 more
wiley +1 more source
Influenza and Other Respiratory Viruses, Volume 20, Issue 7, July 2026.ABSTRACT Background The 8th International Society for Respiratory Viruses (ISRV) Antiviral Group Conference, held jointly with the 3rd International Meeting on Respiratory Pathogens in Singapore (17–20 September 2025), examined evolving approaches to prevention and management of respiratory infections.
Narmadha Morvil +5 more
wiley +1 more source
, 2022 Introduction: Elderly patients are among the most vulnerable populations during the COVID-19 pandemic. Although hydroxychloroquine and favipiravir, separately and in combination, have been used in the general population, their benefits are unclear ...
Duyan, Murat, ÖZTURAN, İBRAHİM ULAŞ
core +1 more source